Top

generating

the breakthroughs to heal

Press releases

We’re meeting milestones in our quest to accelerate healing.

2026

26 March 2026

Noveome Biotherapeutics Announces Positive Data Safety Monitoring Board Recommendation in ongoing NEC Clinical Trial

2025

23 April 2025

Noveome Biotherapeutics, Inc. Completes $51 million Series E Financing to Support Clinical Trials in NEC

2024

14 November 2024

Noveome Biotherapeutics, Inc. Announces Completion of Treatment of the First Baby in its Phase 1-2 Clinical Trial Evaluating ST266 in the Treatment of Necrotizing Enterocolitis in Premature Infants

2023

12 December 2023

Noveome Biotherapeutics, Inc. Receives FDA Notification to Proceed with its Phase 1-2 Clinical Trial in Treatment of NEC

2022

24 May 2022

Noveome Biotherapeutics, Inc. Receives Rare Pediatric Disease Designation and Orphan Drug Designation for the Treatment of Necrotizing Enterocolitis in Neonates

2021

1 June 2021

Noveome Biotherapeutics, Inc. and SipNose, Ltd. Announce Commercial License Agreement For SipNose Cribriform Targeted Device

2020

12 June 2020

Noveome Biotherapeutics Announces Positive Data for Phase 2 Clinical Trial of ST266 in Patients with Persistent Corneal Epithelial Defects

2019

13 June 2019

Noveome Biotherapeutics, Inc. Doses First Patient in Phase 2 Open Label Clinical Trial Evaluating Topical Ocular Delivery of ST266 For the Treatment of Persistent Corneal Epithelial Defects

2018